Ocugen shares surge 11.03% intraday after OCU410 gene therapy phase 2 trial shows 46% lesion growth reduction with no serious adverse events and $22.5M stock issuance expected.

Ocugen surged 11.03% intraday, driven by the announcement of positive phase 2 trial data for OCU410 gene therapy on January 15, 2026, showing a 46% reduction in lesions without serious adverse events, and an expected $22.5 million common stock issuance on January 22, 2026, with net proceeds of approximately $20.8 million allocated for general corporate purposes.